Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112

Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials

“…1b, c. Although none of the 9 trials described blinding of participants and personnel and of outcome assessment, our primary end point was overall survival, which was not likely to be influenced by lack of blinding [8]. One trial [23] that only reported an abstract and many important data could not be acquired was considered had high bias in incomplete outcome data and selective reporting items. One study [25] that was closed early and another study [26] that only reported preliminary results were considered have other bias.…”

“…Seven [5-7, 21, 22, 24, 25] of the 9 trials were published in full texts and two [23,26] in abstracts. Four studies [5][6][7]23] were phase III, and five [21,22,[24][25][26] were phase II clinical trials. The detail regimens and baseline characteristics of the 9 trials are listed in Tables 1 and 2, respectively.…”

“…1a [11][12][13][14][15][16][17][18][19][20]. Thus, 9 trials were ultimately assessed and analyzed [5][6][7][21][22][23][24][25][26].…”

“…In 2001, Georgoulias et al [7] performed a randomized multicentre trial and concluded that gemcitabine plus docetaxel had comparable activity with platinum-based doublet according to objective response rates, median duration of response, time to tumor progression, overall survival, and 1-year or 2-year survival rates in patients with advanced cancer who had not previously had chemotherapy; and gemcitabine plus docetaxel had the most favorable toxicity profile. After that, eight similar studies to compare the efficacy of gemcitabine plus docetaxe with platinum-based doublets had published [5,6,[21][22][23][24][25][26]. Rubio et al [22] reported that the overall response rate of gemcitabine plus docetaxe was higher than platinum-based doublet.…”

“…Overall response All the 9 trials but one [23] reported overall response data. The pooled RR for overall response indicated that platinum-based regimens also had an advantage in ORR (RR = 0.86, 95% CI = 0.74-0.99, p = 0.03) compared with GD regimens (Fig.…”